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Abstract
Neurally-mediated syncope has a broad clinical spectrum which ranges from typical vasovagal 
syncope on one hand, to those situations in which reflex syncope occurs with uncertain, or even 
apparently absent, triggers or prodromes, on the other hand. Overlap of clinical features is fre-
quent in clinical practice and makes any classification difficult to apply when selecting patients 
for cardiac pacing. Typically, the reflex is both hypotensive and cardio-inhibitory. The rationale 
for efficacy of cardiac pacing is that the cardio-inhibitory reflex is dominant, since there is no 
role for pacing in preventing vasodilatation and hypotension. Establishing a relationship be-
tween symptoms and cardio-inhibitory reflex should be the goal of the clinical evaluation before 
embarking on permanent pacing. Similar efficacy has been observed in patients affected by 
dominant cardio-inhibitory reflex irrespective of the clinical form. In general, cardiac pacing 
should be considered last choice applied only in highly selected patients, i.e. those ≥ 40 years of 
age, affected by severe forms of reflex syncope with recurrences associated with frequent injury, 
often due to the lack of prodromes. Recurrence of syncope may still occur despite cardiac pacing 
in a minority of patients. (Cardiol J 2014; 21, 6: 601–605)
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Evidence from the trials in patients with 
tilt-induced vasovagal syncope
Effectiveness of pacing in tilt-induced va-
sovagal syncope patients has been studied in 
5 multi-center randomized clinical trials [1–5]; 
3 non-blinded trials gave positive results and 2 blin-
ded trials gave negative results. Adding together 
the results of the 5 trials, 318 patients were eva-
luated; syncope recurred in 21% of the paced pa-
tients and in 44% of unpaced patients (p < 0.001). 
A recent meta-analysis of all studies suggested 
a non-significant 17% reduction in syncope from 
the double-blinded studies, and an 84% reduction in 
the studies where the control group did not receive 
a pacemaker (PM) [6].
All these studies have their limitations. 
A comparison of these studies causes slight 
difficulties because of important differences in 
study design, largely focused on patient selection. 
Overall, in typical vasovagal population pacing 
seems to have marginal efficacy. These findings 
suggest caution in implanting a PM based on the 
tilt response. 
Typically, the vasovagal reflex is both hypoten-
sive and cardioinhibitory. The rationale for efficacy 
of cardiac pacing is that the cardio-inhibitory reflex 
is dominant in some patients, since there is no 
role for pacing in preventing vasodilatation and 
hypotension. While there is a growing skepticism 
over diagnostic accuracy of tilt testing (TT) for 
syncope diagnosis, emerging evidence support the 
use of tilt table testing in assessing susceptibility to 
reflex hypotension [7]. In this study it is discussed 
how to decide who can benefit from pacing when 
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Evidence from the trials in patients with 
suspected or certain vasovagal (reflex) 
syncope and electrocardiogram- 
-documented asystole
In 2 observational studies, cardiac pacing 
reduced syncope burden in patients with docu-
mented asystolic syncope by 92% [8] and by 83% 
[9], respectively, but did not prevent all syncopal 
events. In the randomized, double-blind, Third 
International Study on Syncope of Uncertain Etiology 
(ISSUE-3) trial [10], 511 patients ≥ 40 years with 
recurrent reflex syncope received an implantable 
loop recorder (ILR); 89 of them had documentation 
of syncope with ≥ 3 s asystole or ≥ 6 s asystole 
without syncope within 12 ± 10 months, and met 
criteria for PM implantation; 77 of 89 patients were 
randomly assigned to dual-chamber pacing with 
rate drop response or to sensing only. The data 
were analyzed on an intention-to-treat principle. 
During the follow-up, the 2-year estimated syn-
cope recurrence rate was 57% with PM OFF and 
25% with PM ON (log-rank p = 0.039). The risk 
of recurrence was reduced by 57%.
The ISSUE studies focused on subjects affec-
ted by reflex syncope with a mean age of 63 years, 
a history of recurrent syncope beginning in middle or 
older age and frequent injuries probably due to lack 
of a prodrome. Young patients were not included in 
the ISSUE population because they usually have 
a more prolonged prodrome before loss of conscio- 
usness. Although ISSUE-3 proved the efficacy 
of cardiac pacing in highly selected patients, the 
patients who had received pacing therapy still had 
an estimated syncopal recurrence rate of 25% at 
2 years. In ISSUE-3, only about half of the patients 
had a positive TT.
A recent sub-analysis of ISSUE-3 [11] showed 
that syncope recurrence rate was 5% in those 
patients who had negative TT and 55% in those 
who had a positive TT (p = 0.004). The recurrence 
rate of patients with positive TT was similar to 
that observed in controls without pacing. Syncope 
recurrence was independent of the type of response 
during TT. Although an asystolic response during 
TT predicted spontaneous asystole with an accura-
cy of 86%, the study was unable to show a benefit 
greater than in the patients with non-asystolic 
responses.
Before ISSUE-3, cardiac pacing for reflex syn-
cope had only been evaluated in patients with a po-
sitive TT; no indication for pacing in patients with 
negative TT existed. By showing that tilt-negative 
patients are those who benefit most from cardiac 
pacing, ISSUE-3 inverts previous assumption on 
indications for pacing. The observed 5% recurren-
ce rate with pacing is similar to that observed in 
patients paced for intrinsic bradycardia. Thus, PM 
therapy might be offered to these patients with the 
same confidence as in patients with intrinsic sinus 
node disease or atrioventricular (AV) block.
Similarly, in carotid sinus syndrome patients 
who also had positive TT there was 2.7-fold greater 
syncope recurrence probability after dual chamber 
pacing than in those with negative TT [12]. In these 
2 types of reflex syncope, when tilt-testing is positive 
caution should be recommended over PM implan-
tation. However, the above results are based on 
a single sub-study whose findings cannot be taken 
as conclusive and need to be confirmed by other stu-
dies before they are accepted in the clinical practice.
Evidence from the trials in patients  
with carotid sinus syndrome
The evidence supporting the benefit of cardiac 
pacing in patients affected by carotid sinus syncope 
(CSS) is limited to few small controlled trials and 
retrospective observational studies. In a MedLine 
search among peer-review journals in English 
language of the articles dealing with natural and 
unnatural history of CSS (case reports excluded), 
12 studies reported sufficient follow-up data for 
analysis. In total, they reported the natural history 
up to 5 years of follow-up of 305 patients and the 
effect of cardiac pacing on other 601 patients affected 
by severe recurrent syncope [13].
The studies were largely heterogeneous with 
regard to selection of patients, duration and po-
sition (supine or standing) of the carotid sinus 
massage, criteria for identification of mixed forms 
of carotid sinus syndrome and different mode 
of pacing (single- vs. dual-chamber). In general, 
with pacing, syncopal recurrence rate during the 
follow-up ranged between 0% and 20%, whereas 
the recurrence of syncope was always higher in 
untreated patients who showed a rate between 20% 
and 60%. In a meta-analysis of 3 studies [14–16] 
with a control group of untreated patients, syncope 
recurred in 9% of 85 patients treated with PM and 
in 38% of 91 controls (relative risk = 0.24; 95% CI 
0.12–0.48). In a large registry of 169 consecutive 
patients treated with PM, the actuarial estimate 
of syncopal recurrence was 7% at 1 year, 16% at 
3 years and 20% at 5 years [17].
Two variables are well known to hamper the 
efficacy of pacing therapy in CSS patients. These 
are mixed forms and the association with positivity 
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of TT of carotid sinus syndrome. Due to lack of 
a standardized methodology of execution of the ca-
rotid sinus massage, the prevalence of mixed forms 
shows a great variability among different studies. 
The prevalence of mixed forms was higher in those 
studies in which the massage was prolonged ≥ 10 s 
and performed in standing position, and also when 
the magnitude of the vasodepressor component 
was assessed after suppression of the cardio-
inhibitory component by i.v. atropine [14, 18–21]. 
For patients who had positive TT (bradycardia and 
hypotension), there was a 2.7-fold greater syncope 
recurrence probability after dual chamber pacing 
than in those with negative TT [21]. When tilt-
testing is positive, caution must be recommended 
over PM implantation.
In conclusion, cardiac pacing is effective in 
preventing recurrences of syncope in CSS patients, 
but syncopal recurrence is expected to occur in up 
to 20% of patients within 5 years.
Evidence from the trials in patients  
with adenosine-sensitive syncope
Common clinical features characterize “low 
adenosine syncope” which has been recently de-
scribed in patients who have an otherwise unexpla-
ined syncope with sudden onset without prodromes 
and a normal heart and normal electrocardiogram 
(ECG). These patients typically have a low plasma 
adenosine value below 0.36 mmol/l (normal values 
in healthy subjects range 0.32–2.80 mmol/l) and 
show an increased susceptibility to exogenous 
adenosine injection, i.e., adenosine triphosphate 
and adenosine tests. In those patients in whom 
a spontaneous ECG could be recorded at the time of 
a spontaneous syncope, the ECG showed paroxysmal 
AV block with one or multiple consecutive pau-
ses, without P-P cycle lengthening or PR interval 
prolongation. In these patients, cardiac pacing was 
very effective in preventing syncopal recurrences 
[22, 23].
The role of the adenosine triphosphate and 
adenosine tests is controversial in identifying such 
patients. Three studies showed no correlation 
between AV block induced by adenosine triphos-
phate and ECG findings (documented by ILR) 
during spontaneous syncope [24–26]. Thus, the 
low predictive value of the test does not support 
its use as a solitary diagnostic test for selecting 
patients for cardiac pacing. In a small multi-center 
trial [27], performed on 80 highly selected elderly 
patients with unexplained syncope who had a po-
sitive response to intravenous injection of a bolus 
of 20 mg of adenosine triphosphate, dual-chamber 
cardiac pacing significantly reduced 2-year syncopal 
recurrence from 69% in the control group to 23% 
in the active group with an estimated proportional 
hazard ratio of 0.25 (95% CI 0.12–0.56).
Choice of pacing mode
Dual-chamber pacing was used in almost all 
trials with a rate drop response feature of the 
PM that instituted rapid DDD pacing if the device 
detected a rapid decrease in heart rate, but no 
comparison with conventional dual-chamber pacing 
was ever made. No comparison with VVI pacing was 
performed. In the absence of comparative studies, 
the Task Force of the European Society of Cardio-
logy was unable to make an evidence-based specific 
recommendation on the choice of pacing mode. 
Nevertheless, this Task Force believes that dual-
-chamber should be preferred over single-chamber 
ventricular pacing in order to avoid the risk of PM 
syndrome caused by the latter modality [28].
Conclusions
Pacing for neurally-mediated syncope: 
How to decide?
It must be emphasized that the decision to 
implant a PM needs to be undertaken in the clinical 
context that is a benign, not life-threatening condi-
tion. The condition typically affects young patients 
(for whom there is little systematic evidence for 
pacing). The fact that pacing is effective in some 
patients with reflex syncope does not mean that it 
is always necessary. A placebo effect has also been 
suggested as the apparent cause for benefit in some 
patients. Nevertheless, for a highly symptomatic 
patient with recurrent and frequent asystolic reflex 
syncope, for whom the evidence of concomitant 
hypotension is not substantiated, pacing may be 
considered an option.
However, in patients with reflex syncope, car-
diac pacing should be the last therapeutic choice 
after other options are tried and should only be 
considered in highly selected patients, i.e. those 
≥ 40 years of age, affected by severe forms of reflex 
syncope with recurrences associated with frequent 
injury, often due to the lack of prodrome. It is likely 
that younger patients who have syncope preceded 
by prodromes would not benefit from PM therapy 
to the same extent; pacing should be avoided with 
very few exceptions. The decision tree reported in 
Figure 1 is a practical algorithm which summarizes 
the available data from the trials. 
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